Safety issues with the ALK inhibitors in the treatment of NSCLC: A systematic review

Barsevick, 2013, Recommendations for high-priority research on cancer-related fatigue in children and adults, J. Natl. Cancer Inst., 105, 10.1093/jnci/djt242 Camidge, 2012, Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study, Lancet Oncol., 13, 1011, 10.1016/S1470-2045(12)70344-3 Cho, 2017, ASCEND-8 : a randomized phase 1 study of Ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK) -rearranged metastatic non – small cell lung Cancer (nsclc), J. Thorac. Oncol., 12, 1357, 10.1016/j.jtho.2017.07.005 Christensen, 2007, Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma, Mol. Cancer Ther., 6, 3314, 10.1158/1535-7163.MCT-07-0365 Crino, 2016, Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2, J. Clin. Oncol., 34, 2866, 10.1200/JCO.2015.65.5936 Felip, 2015, ASCEND-3: a single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC), J. Clin. Oncol., 33 Felip, 2016, Phase 2 study of ceritinib in ALKi-naïve patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC): whole body responses in the overall pt group and in pts with baseline brainmetastases (BM), Ann. Oncol., 27 Genentech, Inc. Alecensa. 2015 www.accessdata.fda.gov/drugsatfda_docs/label/2015/208434s000lbl.pdf Available from [Accessed 21/4/2017]. Gettinger, 2016, Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial, Lancet Oncol., 2045, 1 Heckmann, 2005, Zinc gluconate in the treatment of dysgeusia - a randomized clinical trial, J. Dent. Res., 84, 35, 10.1177/154405910508400105 Hida, 2017, Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial, Lancet [Internet], 390, 29, 10.1016/S0140-6736(17)30565-2 Hovan, 2010, 1081 Ikeda, 2015, Interstitial lung disease induced by alectinib (CH5424802/RO5424802), Jpn. J. Clin. Oncol., 45, 221, 10.1093/jjco/hyu183 Inamura, 2008, EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers, J. Thorac. Oncol., 13, 10.1097/JTO.0b013e31815e8b60 Johung, 2016, Extended survival and prognostic factors for patients with ALK -Rearranged non–Small-Cell lung Cancer and brain metastasis, J Clin Oncol [Internet], 34, 123, 10.1200/JCO.2015.62.0138 Katayama, 2015, Therapeutic targeting of anaplastic lymphoma kinase in lung Cancer: a paradigm for precision Cancer medicine, Clin. Cancer Res., 15;21, 2227, 10.1158/1078-0432.CCR-14-2791 Kawase, 2011, Change in serum KL-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced interstitial lung disease, Respir. Res., 12, 97, 10.1186/1465-9921-12-97 Kim, 2016, Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial, Lancet Oncol., 17, 452, 10.1016/S1470-2045(15)00614-2 Kim, 2016, Brigatinib (BRG) in Crizotinib (CRZ)-Refractory ALK+ Non−small Cell Lung Cancer (NSCLC): efficacy and safety results from ALTA, a pivotal randomized phase 2 Trial, Ann. Oncol., 27 Kim, 2017, Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase – positive non – small-cell lung Cancer : a randomized, multicenter phase II trial, J. Clin. Oncol., 35, 10.1200/JCO.2016.71.5904 Koizumi, 2015, Successful treatment of crizotinib-induced dysgeusia by switching to alectinib in ALK-positive non-small cell lung cancer, Lung Cancer., 88, 112, 10.1016/j.lungcan.2015.01.018 Liu, 2015, Crizotinib reduces the rate of dark adaptation in the rat retina independent of ALK inhibition, Toxicol. Sci.: Official J. Soc.Toxicol., 143, 116, 10.1093/toxsci/kfu213 Lucena-Araujo, 2016, De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers, Lung Cancer [Internet], 99, 17, 10.1016/j.lungcan.2016.06.006 Matsumoto, 2011, Abstract 4385: effect on retinal function as a mechanism for vision disorders with crizotinib (PF-02341066), Cancer Res., 15;71 Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, PLoS Med., 21;6 National Cancer Institute Cancer Nishio, 2015, Phase I study of ceritinib (LDK378) in japanese patients with advanced, anaplastic lymphoma kinase-rearranged, J. Thorac. Oncol., 10, 1058, 10.1097/JTO.0000000000000566 Ou S-HI, Ahn JS, De Petris L, Govindan R, Yang JC-H, Hughes B, et al. Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. J Clin Oncol. 2018 Mar 1;34(7):661–668. Park, 2015, Efficacy and safety of ceritinib in patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and baseline brainmetastases (BM) – results from ASCEND-2 and, Ann. Oncol., 26 Pfizer Labs, 2015 Rangachari, 2017, Cases of ALK-rearranged lung cancer with 5-year progression-free survival with crizotinib as initial precision therapy, J. Thorac. Oncol., 12, e175, 10.1016/j.jtho.2017.06.002 Scagliotti, 2016, Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): results from the confirmatory phase 3 ASCEND-5 study, Ann. Oncol., 1;27 Schnell, 2012, cK-Positive (ALK+) Advanced Non-Small Cell Lung Cancer (NSCLC), J. Clin. Oncol., 30, 7598, 10.1200/jco.2012.30.15_suppl.7598 Seto, 2013, (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study, Lancet Oncol., 14, 590, 10.1016/S1470-2045(13)70142-6 Shaw, 2013, Crizotinib versus chemotherapy in advanced ALK-positive lung cancer, N. Engl. J. Med., 368, 2385, 10.1056/NEJMoa1214886 Shaw, 2014, Ceritinib in ALK -Rearranged non–Small-Cell lung Cancer, N. Engl. J. Med., 370, 1189, 10.1056/NEJMoa1311107 Shaw, 2016, Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial, Lancet Oncol., 17, 234, 10.1016/S1470-2045(15)00488-X Shaw, 2017, Ceritinib versus chemotherapy in patients with ALK -rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial, Lancet Oncol., 18, 874, 10.1016/S1470-2045(17)30339-X Shohdy KS, Abdel-Rahman O. Risk of pneumonitis with different immune checkpoint inhibitors in NSCLC. Ann Transl Med. 2018;5 September (17):365–365. Soda, 2007, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer, Nature., 2;448, 561, 10.1038/nature05945 Solomon, 2014, First-line crizotinib versus chemotherapy in ALK -Positive lung Cancer, N. Engl. J. Med., 371, 2167, 10.1056/NEJMoa1408440 Soria, 2017, First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study, Lancet, 4;389, 917, 10.1016/S0140-6736(17)30123-X Tamura T, Kiura K, Seto T, Nakagawa K, Maemondo M, Inoue A. Three-Year Follow-Up of an Alectinib Phase I / II Study in ALK -Positive Non – Small-Cell Lung Cancer : AF-001JP. 2017. Wilson, 2015, A functional landscape of resistance to ALK inhibition in lung Cancer, Cancer Cell, 27, 397, 10.1016/j.ccell.2015.02.005 Yoneda, 2017, Interstitial lung disease associated with crizotinib in patients with advanced non-small-cell lung cancer: independent review of four PROFILE trials, Clin Lung Cancer, 18, 472, 10.1016/j.cllc.2017.03.004